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1–42 b-Amyloid peptide requires PDK1/nPKC/Rac 1
pathway to induce neuronal death
L Manterola1,12, M Hernando-Rodrı´guez2,12, A Ruiz3,4, A Apraiz5, O Arrizabalaga5, L Vello´n6, E Alberdi3,4, F Cavaliere3,4, HM Lacerda7,
S Jimenez8,9, LA Parada10, C Matute3,4 and JL Zugaza4,5,11
1–42 b-Amyloid (Ab1–42) peptide is a key molecule involved in the development of Alzheimer’s disease. Some of its effects are
manifested at the neuronal morphological level. These morphological changes involve loss of neurites due to cytoskeleton
alterations. However, the mechanism of Ab1–42 peptide activation of the neurodegenerative program is still poorly understood.
Here, Ab1–42 peptide-induced transduction of cellular death signals through the phosphatidylinositol 3-kinase (PI3K)/
phosphoinositol-dependent kinase (PDK)/novel protein kinase C (nPKC)/Rac 1 axis is described. Furthermore, pharmacological
inhibition of PDK1 and nPKC activities blocks Rac 1 activation and neuronal cell death. Our results provide insights into an
unsuspected connection between PDK1, nPKCs and Rac 1 in the same signal-transduction pathway and points out nPKCs and
Rac 1 as potential therapeutic targets to block the toxic effects of Ab1–42 peptide in neurons.
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Introduction
Small GTPases of the Rho family, whose best-characterized
members include Rho A, Rac 1 and Cdc42, are key players in
complex signaling networks that control normal activity in
most if not all cell types.1 Like other small GTPases, Rho
GTPases function as molecular switches to control cellular
signaling pathways. They are present in two conformations,
an inactive form loaded with GDP and an active form loaded
with GTP. Transition from the inactive to the active state is
regulated by guanine nucleotide exchange factors.2 In their
active configuration, GTPases interact with downstream
effector molecules to promote a variety of biological
responses.3,4 GTPases of the Rho family are best known for
controlling the appropriate actin cytoskeleton reorganization
in response to extracellular signals, although their implication
in additional biological processes, such as gene expression
regulation, cell polarity and cell migration have also been
reported.1
As these monomeric G proteins are implicated in almost all
aspects of cell biology,5 changes in their regulatory cycles can
affect normal cell functionality in an irreversible manner.
Signaling pathways that originated from deregulated GTPase
activities can be involved in cell transformation and metas-
tasis,6,7 in Wiskott–Aldrich syndrome,8 faciogenital dysplasia,
Tangier disease9 and other pathologies. Recently, it has been
shown that they may also be implicated in Alzheimer’s
disease (AD).10 It is well established that RhoGTPases
control cytoskeleton dynamics in neurons, therebymodulating
synaptic plasticity.11 In fact, AD entails progressive dendritic
spine loss, synaptic dysfunctions and morphological changes
in dendrites.10 In normal brain, neuronal Rho A attaches to
synapses and dendritic microtubules; however, in AD Rho A
the expression is decreased in synapses and increased in
dystrophic neuritis.10
The molecular mechanisms leading to the development of
AD are not fully characterized. This neuropathology is
associated with massive accumulation of two types of protein
aggregates: senile plaques that are constituted mostly by
1–42 b amyloid (Ab1–42) peptide and by neurofibrillary tangles
containing hyperphosphorylated Tau protein.12 There is
mounting evidence that Ab1–42 peptide mediates many
aspects of AD pathogenesis. In vitro this peptide is toxic to
endothelial cells,13,14 smooth muscle cells,15 astrocytes,16
neurons17,18 and oligodendrocytes.19 The mechanisms
through which Ab1–42 peptide exerts its cytotoxic action are
not fully understood. Currently, there are ongoing efforts to
discover the signaling pathways that are mediated by the
Ab1–42 peptide. Several signaling cascades may be involved
in cell damage and they appear to be activated by the Ab1–42
peptide, including oxidative stress generation,18,20 impaired
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Ca2þ homeostasis,21 mitochondrial dysfunction,22 genera-
tion of NO23 and microglia activation.24
Here, Ab1–42 peptide use of cellular machinery for signal
transduction leading to neuronal cell death in the cell line
SN4741 theat originated from mouse substantia nigra was
studied25,26 in primary embryonic cortical neurons from rats
as well as in neuronal organotypic cultures of the hippocam-
pus and the entorhinal cortex. This signaling cascade involves
specifically Rac 1 GTPase, which is regulated upstream by
the phosphatidylinositol 3-kinase (PI3K)/phosphoinositol-
dependent kinase (PDK)1/ novel protein kinase C (nPKC)
pathway. This novel molecular characterization identifies
nPKCs and Rac 1 as potential therapeutic targets to block
neuronal death program induced by the b-amyloid peptide.
Materials and methods
Reagents. AKT inhibitor II, GF 109203X, Go¨ 6976 and
Rottlerin were obtained from Calbiochem (Darmstadt, Ger-
many). HFIP (1,1,1,3,3,3-hexafluoro-2-propanol), LY294002
(2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) hydro-
chloride, phorbol 12 myristate 13 acetate (PMA), 6-mercap-
topurine (6-MP) and dimethylsulfoxide were obtained from
Sigma (Dorset, UK). Rac 1 inhibitor NCS23766 (N-(N-(3,5-
difluorophenacetyl-L-alanyl))-S-phenylglycine) was obtained
from Calbiochem (Merck Millipore, Darmstadt, Germany).
OSU03012 was obtained from Cayman (Ann Arbor, MI, USA)
and Ab1–42 peptide was obtained from Bachem (Weil am
Rheim, Germany). Mouse monoclonal anti-Cdc42 and anti-
Rac 1 antibodies were obtained from Upstate Biotechnology
(Lake Placid, NY, USA). Rabbit polyclonal anti-Rho A
antibody was obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Rabbit polyclonal anti-phospho-
p21-activated kinase (PAK)1 and anti-PAK1 antibodies and
mouse monoclonal anti-enhanced green fluorescent protein
(EGFP) antibody were obtained from Cell Signaling Technol-
ogy (Danvers, MA, USA), and mouse anti-HA was obtained
from Covance (Berkeley, CA, USA).
Preparation of synthetic Ab oligomers. Ab1–42 oligomers
were prepared as previously described by Klein et al.27
Briefly, Ab1–42 peptide was initially dissolved to 1mM in HFIP
and separated into aliquots in sterile microcentrifuge tubes.
HFIP was totally removed under vacuum in a speedvac
system and the peptide film was stored desiccated at
 80 1C. For the aggregation protocol, the peptide was first
resuspended in dry dimethylsulfoxide to a concentration of
5mM and Hams F-12 cell culture medium (PromoCell,
Labclinics, Barcelona, Spain) was added to bring the peptide
to a final concentration of 100mM and incubated at 4 1C for
24 h. Preparation was then centrifuged at 14 000g for 10min
at 4 1C to remove insoluble aggregates and supernatant
containing soluble Ab1–42 peptide was transferred to clean
tubes and stored at 4 1C.
Natural oligomers from double transgenic
PS1D9xAPPswe (PS1APP) mice. Soluble protein extrac-
tion (soluble fractions) from 18-month-old PS1APP double
transgenic and non-transgenic (wild-type (WT)) mice
were obtained by ultracentrifugation of homogenates, as
described previously.28 Protein concentration present in
soluble fractions was determined by the method of Lowry
et al.29 To diminish the potential inter-individual variability,
soluble fractions from four different mice were pooled.28 For
in vitro experiments, soluble fractions were thawed immedi-
ately before use, diluted with Dulbecco’s modified Eagle’s
medium (w/o fetal bovine serum (FBS)), sterilized and added
to cultures.
Cell culture and DNA transfection. SN4741 cells were
maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% FBS, 4mM L-glutamine, 3.7 g sodium
bicarbonate and 4.5 g l 1 glucose w/o sodium pyruvate,
100 ngml 1 streptomycin and 100Uml 1 of penicillin (all
from Invitrogen, Alcobendas, Madrid, Spain). They were
maintained at 37 1C and 5% CO2. For transient transfection
assays, cells were washed two times with PBS and
trypsinized, and then 5 106 cells (per condition) were
resuspended into 200ml of serum-free medium containing
either 10 mg pEGFP or pEGFP-PKCy or pcDNA3-HA-Tiam-1
were electroporated at 260V, 950mF in a Gene Pulser Xcell
Electroporator (Bio-Rad, Alcobendas, Madrid, Spain). Cells
were collected into 10ml of complete Dulbecco’s modified
Eagle’s medium for 24 h, washed and then cultured in serum-
free medium for additional 24 h. After this period, transfected
cells were pretreated either with Rottlerin or not for 1 h
followed by treatment with Ab1–42 peptide.
Primary neuron cultures were obtained from the cortical
lobes of E18 Sprague–Dawley rat embryos, as described
previously.21 Cells were resuspended into 0.5% B27-Neuro-
basal medium plus 10% FBS and then seeded onto 6-well
plates at 1.5 106 cells per well. After 1 day, the medium was
replaced by serum-free 0.5% B27-supplemented neurobasal
medium. Cell cultures were essentially free of astrocytes and
microglia and they were maintained at 37 1C and 5% CO2.
Cultures were used 8–10 days after plating. For transient
transfection assays, rat neurons obtained as described above
were transfected with 3 mg pEGFP or pEGFP-RBD (Rac
binding domain of PAK1)30 using Amaxa Rat Neuron
Nucleofector Kit (Lonza, Basel, Switzerland), according to
the manufacturer’s instructions. For microscopy analysis,
transfected cells were plated onto glass-bottom m-dishes (Ibidi
GmbH, Munich, Germany), maintained as described above
and used 8 days after plating.
Preparation of organotypic cultures and cell viability.
Rat brains were removed and the two separated hemi-
spheres were placed in Hank’s balanced salt solution
medium. Thalamus and midbrain were removed and each
hemisphere was sliced using a tissue chopper (McIlwan
Tissue Chopper; Campden Instruments, Lafayette, IN, USA)
to obtain 400mm coronal slices. The entorhinal cortex,
connected to the hippocampus, was isolated using a
dissection microscope, two slices were plated on each
Millicell CM culture inserts (Millipore Ibe´rica, Madrid, Spain)
and maintained in Neurobasal medium supplemented with
0.5% B27, 25% horse serum, 25% Hank’s balanced salt
solution and 25mgml 1 gentamycin at 37 1C for 7 days.
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Hippocampus–entorhinal cultures were exposed to Ab1–42
peptide oligomers at 100 nM for 4 additional days. Inhibitors
were added to cultures 30min before the Ab1–42 peptide
oligomers. Slices were stained with 10 mM propidium iodide
for 2 h at 37 1C, washed two times with PBS for 10min and
fixed with 4% paraformaldehyde in PBS for 40min at room
temperature.21 Subsequently, slices were excited with 510–
560nm light and emitted fluorescence was acquired at
610 nm using a rhodamine filter with an inverted fluorescence
microscope (Cell Observer Z1; Zeiss, Jena, Germany).
Propidium iodide fluorescence images were captured with a
Plan NeoFluar  2.5 objective (Zeiss), using an EM CCD
camera (Hamamatsu Photonics, Hamamatsu, Japan;
C9100-13) and controlled by Axio Vision program (Zeiss).
Images were analyzed with the ImageJ analysis program
(NIH, Bethesda, MD, USA).
Rho A, Rac 1 and Cdc42 activation assays. Rho family
GTPases were pulled down as described previously.30
Briefly, cells deprived of serum for 24 h were pretreated with
inhibitors or not for 1 h and subsequently treated with Ab1–42
peptide oligomers for the indicated times and lysed. Cell
lysates were collected after centrifugation and incubated for
1 h at 4 1C with specific GST-fusion proteins coupled to
glutathione-sepharose beads. Precipitated proteins were
eluted, electrophoresed by sodium dodecyl sulfate-polya-
cryalmide gel electrophoresis and analyzed by western
blotting with specific antibodies. Immunoreactive bands were
visualized using ECL.
PAK1 phosphorylation assay. Primary neuron cultures
were pretreated or not with Rac 1 inhibitor for 1 h.
Subsequently, cells were treated with natural oligomers from
transgenic mice for 30min, as indicated. Cultures were
washed with PBS, and lysed directly in Laemmli buffer.
Lysates were electrophoresed by sodium dodecyl sulfate-
polyacryalmide gel electrophoresis and analyzed by western
blotting with anti-phospho-PAK1 and anti-PAK1 antibodies.
Immunoreactive bands were visualized using ECL.
Immunoprecipitation assay. SN4741 cells transfected with
pcDNA3-HA-Tiam-1 were treated or not with Ab1–42 peptide
oligomers for 30min, washed three times in ice-cold PBS and







Figure 1 1–42 b-Amyloid (Ab1–42) peptide exposure leads to cytotoxicity and Rac 1 activation in neurons. (a) Histogram represents the mean of three independent
experiments±s.e.m. (*Po0.05, **Po0.01, comparing control cells vs Ab1–42 peptide-treated cells). (b) Dot plots represent the distribution of early apoptotic (lower right,
annexin VþPI ), necrotic (upper left, annexin VPIþ ), late apoptotic (upper right, annexin VþPIþ ) and viable (lower left, annexin VPI ) cells. Dot plots are
representative of three independent experiments. Histograms represent mean±s.e.m. values of three independent experiments. (c) Small GTPases activation. SN4741 cells
were treated (þ ) or not ( ) with 5 mM Ab1–42 peptide for 1 h or 10 min with 10% fetal bovine serum (FBS) and cell extracts were used to measure Rho A, Rac 1 and Cdc42
activation (loaded with GTP) by affinity precipitation assays. Results are representative of three independent experiments. Panels 2, 4 and 6 show total small GTPases in cell
lysates. (d) Kinetics of Rac 1 activation induced by Ab1-42 peptide. Results are representative of four independent experiments. (e) and (f) Ab1–42 peptide activates Rac 1 in a
dose-dependent manner in SN4741 cells and primary neurons. Immunoblot depicts a representative experiment out of three. Lower panels in (d–f) show total Rac 1 in cell
lysates. PI, propidium iodide; W.B., western blot.
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4 1C for 2 h with the anti-HA antibodies. Immune complexes
were recovered using Gamma Bind Plus Sepharose beads
(GE Healthcare, Pittsburgh, PA, USA), washed and eluted
from beads using 2 Laemmli’s buffer, electrophoresed by
sodium dodecyl sulfate-polyacryalmide gel electrophoresis
and analyzed by western blotting with anti-threonine or
anti-HA antibodies. Immunoreactive bands were visualized
using ECL.
Cell viability and toxicity assays. SN4741 cells were
seeded at 104 cells per well in a 96-well plate, serum-starved
for 24 h, pretreated with different inhibitors for 1 h, as
indicated, and treated or not with Ab1–42 peptide oligomers
for 24 h. Primary neuronal cultures were pretreated or not
with Rac 1 inhibitor for 1 h. Subsequently, cells were treated
with synthetic Ab1–42 peptide or natural oligomers from
transgenic mice for 24 h, as indicated. Cell survival was
measured with CellTiter 96 Non-Radioactive Cell Prolifera-
tion Assay (MTT) (Promega, Madison, WI, USA), according
to the manufacturer’s instructions.
In SN4741 cells apoptosis was assessed staining cells with
annexin V-FITC (FITC Annexin V Apoptosis detection kit; BD,
Becton Dickinson, Franklin Lakes, NJ, USA) according to the
manufacturer’s instructions. A total of 3 106 cells per
100mm plates were serum-starved for 24 h, pretreated with
different inhibitors for 1 h as indicated and treated with Ab1–42
peptide oligomers for 24 h. Cells were detached and 1 106
cells per ml were incubated with annexin V-FITC and
propidium iodide and analyzed on a FACScan.
In neuronal primary cultures, apoptosis was estimated by
staining cells with annexinV-Cy5 (BD), according to
manufacturer’s instructions. Primary cultures transfected with
either pEGFP or pEGFP-RBD were treated or not with 5 mM
Ab1–42 peptide for 24 h, and live-cell imaging was performed
by laser-scanning confocal microscopy (Olympus Fluoview
FV500, Hamburg, Germany).
Statistical analysis. Student’s t-test for the mean of two-
paired samples was used to determine the significance
between data means (#,*Po0.05, **Po0.01 and
***Po0.001).
Results
Ab1–42 peptide activates Rac 1 GTPase in a dose- and
time-dependent manner. We examined whether neuronal
cell line SN4741 was sensitive to the toxicity induced by the
Ab1–42 peptide-derived diffusible ligands (ADDLs).
27 Cells
were incubated with increasing concentrations of Ab1–42
peptide for 24 h and cell viability was determined by MTT
assay. As shown in Figure 1a, cell viability, measured as
mitochondrial metabolic activity, correlated inversely with the
concentration of Ab1–42 peptide added. Nevertheless, MTT
assay is a colorimetric method that cannot discriminate
whether cells die by necrosis or apoptosis.31,32
Therefore, SN4741 cells were treated (þ ) or not ( ) with
1.25mM Ab1–42 peptide (a concentration that reduced cellular
viability by 50%, as shown in Figure 1a) for 24 h and apoptosis
was determined by staining plasmamembrane with annexin V
combined with propidium iodide followed by flow cytometry
analysis. As shown in Figure 1b (histogram graphs and dot
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Figure 2 Rac 1 activation induced by 1–42 b-amyloid Ab1–42 peptide requires the involvement of protein kinase C (PKC), phosphatidylinositol 3-kinase (PI3K) and
phosphoinositol-dependent kinase (PDK)1 in neurons. (a–f) SN4741 cells (left panels) and primary neurons (right panels) were pretreated with the indicated inhibitors for 1 h
and then treated or not with 1.25mM Ab1–42 peptide for 30 min or 1mM phorbol 12 myristate 13 acetate (PMA) for 15 min and lysed. Cell extracts were used to measure Rac 1
activation by affinity precipitation assays (Rac 1-GTP); a sample of total cell lysate was used to determine the PKD phosphorylation treatment, Rac 1 shows total Rac 1 in cell
lysates and tubulin immunoblot represents the loading protein control. Results are representative of five (a, d and e) and three (b and c) independent experiments,
respectively.
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28% (Figure 1b, empty bars, left histogram vs right histogram)
and increased apoptosis in the same proportion, that is, early
apoptosis from 6 to 19% (Figure 1b, gray bars, left histogram
vs right histogram) and late apoptosis from 14 to 46%
(Figure 1b, solid bars, left histogram vs right histogram).
Percentage of annexinV /propidium iodideþ cells in both
untreated and treated cells was maintained at around 6%
(Figure 1b, hached bars, left histogram vs right histogram).
Taken together, these observations indicate that SN4741 cell
line is suitable for studying Ab1–42 peptide-induced apoptosis.
As small GTPases of the Rho family are key regulators of
cell signaling, the hypothesis that they can be activated by
Ab1–42 peptide treatment was tested. SN4741 cells were
treated with 5 mM Ab1–42 peptide for 1 h; lysed and small
GTPases were pulled down and visualized, as described in
the Materials and methods section. As shown in Figure 1c,
Ab1–42 peptide stimulated Rac 1 activation (Rac 1-GTP);
however, this peptide was unable to activate either Rho A
or Cdc42. To verify whether these GTPases were func-
tional in this cellular system, cells were stimulated with 10%
FBS for 10min and processed in the same manner as
cells treated with Ab1–42 peptide. All three GTPases
were effectively activated under this stimulatory condition
(Figure 1c, line 3).
The effect of Ab1–42 on Rac 1 activation was characterized
further by examining the kinetics of activation of this GTPase.
SN4741 cells were treatedwith 5 mMAb1–42 peptide at different
times, as indicated in Figure 1d. Maximal activation of Rac1
was observed 30min after peptide addition and decreased
progressively reaching basal levels 60min thereafter
(Figure 1d). The optimum time to show Rac 1 activation was
at 30min after stimulation, which was taken into consideration
when performing the dose–response curvewith SN4741 cells.
Minimal concentration of Ab1–42 peptide required to produce
maximal activation of Rac 1 was 1.25mM, as shown in
Figure 1e. This result was confirmed using primary neuron
cultures, where again, the minimal Ab1–42 peptide concentra-
tion to induce maximal Rac 1 activation was 1.25 mM
(Figure 1f). These results prompted us to characterize the
signaling cascades used by the Ab1–42 peptide to activate
Rac 1 and to determine whether they are involved in neuronal
cell death.
Signaling cascade activated by A1–42 peptide: the PI3K
and Rac 1 connection. PKC family is one of the most
important serine–threonine kinase families implicated in early
intracellular signal transduction. We initiated the study








Figure 3 Phosphatidylinositol 3-kinase (PI3K)/ phosphoinositol-dependent kinase (PDK)1/novel protein kinase C (nPKC)/Rac 1 pathway is a target to block SN4741
apoptosis induced by 1–42 b-amyloid (Ab1–42) peptide in vitro. (a, b) SN4741 cells were pretreated or not with pharmacological inhibitors for PI3K, AKT, PDK1, PKC or Rac 1
for 1 h and treated with Ab1–42 peptide oligomers (þ ) or not ( ) for additional 24 h. Results show the mean of: (a) six independent experiments±s.e.m. (**Po0.01,
comparing Ab1–42 peptide vs OSU03012 treatment,
#Po0.05, comparing untreated vs OSU03012 treatment) and (b) four independent experiments±s.e.m. (*Po0.05,
**Po0.01, comparing Ab1–42 peptide vs inhibitors treatments, #Po0.05, comparing untreated vs Rottlerin treatment). (c) SN4741 cells (upper panels) and primary neurons
(lower panels) were pretreated with 7.5mM Rottlerin (þ ) or not ( ) for 1 h and then treated (þ ) or untreated ( ) with 1.25 mM Ab1–42 peptide for 30 min and lysed. Cell
extracts were used to measure Rac 1 activation, and upper and lower second panels show total Rac 1 in cell lysates. Results are representative of four independent
experiments. (d) Tiam-1 threonine phosphorylation induced by Ab1–42 peptide requires the involvement of PKCs. Transfected cells were pretreated with 7.5mM Rottlerin (þ )
or not ( ) for 1 h and then treated (þ ) or left untreated ( ) with 1.25mM Ab1–42 peptide for 30 min and lysed, cell extracts were subjected to immunoprecipitation with anti-
hemagglutinin (HA) antibodies and immunoreactive bands were visualized using anti-phosphothreonine and anti-HA antibodies. Results are representative of three
independent experiments. (e) SN4741 cells were transfected with an empty vector or a plasmid encoding the constitutively active form of PKCy and the effects on Rac 1
activation induced by 1.25 mM Ab1–42 peptide were studied. Immunoreactive bands were visualized using anti-Rac 1 antibodies. Results are representative of three
independent experiments. EGFP, enhanced green fluorescent protein; IP, immunoprecipitation; LY294002, (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one); 6-MP,
6-mercaptopurine; W.B., western blot.
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peptide involved PKCs’ activation. To this end, cell cultures
were pretreated for 1 h with 1mM GF 109203X, a broad-
spectrum inhibitor for PKC family members,33 followed by
treatment with Ab1–42 peptide for 30min. Active Rac 1 was
pulled down and visualized as described above. Here,
inhibition of PKC activity inhibited Rac 1 activation stimulated
by Ab1–42 peptide. Results were obtained with both: SN4741
cells and primary neurons (Figure 2a, upper left and right
panels, respectively). To verify a putative connection
between PKC and Rac 1 activation in these cellular systems,
PMA, a natural analog of DAG, was used to activate directly
PKC. PMA was able to induce Rac 1 activation in both
cellular models (Figure 2b upper left and right panels, lanes 2
and 6). Accordingly, PMA-stimulated Rac 1 activation was
blocked when cells were pretreated with GF 109203X
(Figure 2b, upper left and right panels, lanes 4 and 8). It is
well established that protein kinase D (PKD) requires PKCs
to be phosphorylated and become active.34 Thus, to further
understand the involvement of PKC in Rac 1 activation
stimulated by Ab1–42 peptide, the phosphorylation state of
PKD was examined in the same samples used to check the
involvement of PKC in Rac 1 activation stimulated by Ab1–42
peptide. Results show that Ab1–42 peptide treatment corre-
lated with an increase in PKD phosphorylation (Figure 2c,
third panels, lanes 2 and 5). These results suggest an active
role of PKCs in the Ab1–42 peptide-stimulated Rac 1
activation.
To identify additional components of this novel signal-
transduction pathway, a potential implication of PI3K was
examined. SN4741 cells were pretreated for 1 h with 20 mM
LY294002, a specific inhibitor of PI3Ks, followed by incubation
with 1.25 mM Ab1–42 peptide for 30min. Results show that
LY294002 blocked Rac 1 activation induced by Ab1–42 peptide
(Figure 2c, first panel on the left, lane 3). Similar results were
obtained using primary neurons (Figure 2c, first panel on the
right, lane 6). This result suggests that PI3K mediates Rac 1
activation stimulated by Ab1–42 peptide treatment in SN4741
cells. Furthermore, pretreatment of SN4741 and primary
neuron monolayers with LY294002 resulted in a decrease in
PKD phosphorylation (Figure 2c, third panels, left and right,
lanes 3 and 6, respectively).
The relationship between PI3K, PKC andRac 1 activation in
SN4741 and primary neurons was further probed using PMA,
as described before. PMA was able to induce Rac 1 activation
in both cellular models (Figure 2d, upper left and right panels,
lanes 2 and 6). Moreover, Rac 1 activation was not blocked
when cells were treated with LY294002 (Figure 2d, upper left
and right panels, lanes 4 and 8). Finally, PI3K inhibitor did not
Figure 4 1–42 b-Amyloid (Ab1–42) peptide-induced apoptosis in primary cultures of neurons requires Rac 1 pathway involvement. Confocal images of primary neurons,
showing apoptotic cells. Arrows identify annexin Vþ (blue) cells in (a) enhanced green fluorescent protein (EGFP)þ and untreated cells, (b) EGFPþ and Ab1–42 peptide-
treated cells, (c) EGFP-RBDþ and untreated cells and (d) EGFP-RBDþ and Ab1–42 peptide-treated cells. Scale bar: 50 mm. Histogram bars (e) represents normalized
mean±s.e.m.% of annexin Vþ primary neurons cultures (n¼ 3), *Po0.05 comparing EGFPþ - vs EGFP-RBDþ -treated cells. Scale bar: 50mm. (f) Synthetic Ab1–42
oligomers reduce cortical neuronal cell viability through Rac1. Results represent the mean±s.d. of three independent experiments, *Po0.05 and ***Po0.001 comparing
1.25 and 5mM Ab1–42 peptide vs NCS23766 (N-(N-(3,5-difluorophenacetyl-L-alanyl))-S-phenylglycine) treatment, respectively. (g) Soluble brain fractions, derived from 18-
month-old PS1APP mice induce p21-activated kinase (PAK)1 phosphorylation. PAK1 phosphorylation levels (Ser199/204) were determined by western blot (W.B.).
Membrane was stripped and probed with anti-PAK1 antibody (lower panel). Results are representative of two independent experiments. (h) Soluble brain fractions, derived
from 18-month-old PS1APP mice, reduce cortical neuronal cell viability through Rac 1. Results represent the mean±s.d. of three independent experiments *Po0.05
comparing 10mg PS1APP vs NCS23766 treatment.
Ab1–42 and its putative role on neuronal death
L Manterola et al
6
Translational Psychiatry
affect PKD phosphorylation (Figure 2d, third panels, lanes 4
and 8). Taken together, these results suggested that PI3K is
upstream of PKC-mediated Rac 1 activation.
These results prompted us to investigate further the link
between PI3K and PKC initiated by Ab1–42 peptide. A well-
described enzyme with the ability to connect these two
kinases is the phosphoinositol-dependent kinase 1.35,36
At this point, we hypothesized that PDK1 could be our
candidate connecting PI3K and PKC. To test this hypothesis,
we used the pharmacological inhibitor for PDK1, OSU-03012.
SN4741 cells were pretreated for 1 h with 10 mM OSU-03012
followed by 1.25mM Ab1–42 peptide treatment for 30min.
Results showed that OSU-03012 blocked Rac 1 activation
stimulated by the Ab1–42 peptide (Figure 2e, first panel left,
lane 2 vs lane 3). Similar results were obtained with primary
neurons (Figure 2e, first panel right, lane 5 vs lane 6).
Furthermore, Ab1–42 peptide stimulated PKD phosphorylation
(Figure 2e, third panels, lanes 2 and 5) was blocked by OSU-
03012, both in SN4741 cells (Figure 2e, third panel left, lane 3)
and in primary neurons (Figure 2e, third panel right, lane 6).
These results suggest that PDK1 may have a role in the
signaling pathway that leads to Rac 1 activation in response to
Ab1–42 peptide stimulation.
Ab1–42 peptide activates PI3K/PDK1/PKC/Rac 1 pathway
leading to neuronal death: potential therapeutic targets.
A detailed study of the PI3K/PDK1/PKC/Rac 1 signaling
pathway controlled by the Ab1–42 peptide and its putative role
on neuronal death was carried out. First, examination of
signaling pathway regulated by PI3K and its downstream
targets, PDK1 and AKT, was performed. To this end,
SN4741 cells were pretreated with inhibitors for 1 h before
Ab1–42 peptide addition and maintained in culture for further
24 h. Finally, cell viability was determined by an MTT assay.
As shown in Figure 3a, LY294002 alone decreased SN4741
cell viability in a dose-dependent manner. Consequently, the
inhibitor did not prevent cell death induced by the Ab1–42
peptide. The observed effect was more pronounced when
using AKT inhibitor II than the effect of the Ab1–42 peptide
alone. At 50 mM AKT inhibitor II cell viability was reduced to
o20%. This indicated that both LY294002 and AKT inhibitor
II were toxic to cells on their own. On the other hand, 1 mM
OSU03012 (PDK1 inhibitor) alone increased SN4741 cell
viability compared to untreated cells, but more importantly,
pretreament of cells with 1mM OSU03012 prevented the toxic
effect induced by 1.25 mM Ab1–42 peptide, increasing cell
survival from 50.28 to 78.83% (Figure 3a).
Next, we examined whether PKCs’ were involved in this
neurotoxic pathway initiated by the Ab1–42 peptide. We
showed that GF 109203X was able to inhibit activation of
Rac 1 upon Ab1–42 peptide stimulation. GF 109203X inhibits
both classical and novel PKCs.33,37–39 To differentiate
between classic and novel PKCs, Go¨ 6967, an inhibitor of
classic PKCs (mainly a and b), was chosen, and Rottlerin,
which was initially described as a selective inhibitor of the
novel PKC isoform d was40 subsequently described to inhibit
PKCy also.41,42 As shown in Figure 3b, pretreatment of
SN4741 cells with GF 109203X was partially able to protect
cells against toxicity caused by the Ab1–42 peptide. Cell
cultures treated with 1.25 mM Ab1–42 peptide showed 50.28%
viability; however, GF 109203X protected cell cultures
increasing their viability to 77.96%. In contrast, Go¨ 6967 did
not prevent the toxic effect induced by the peptide, neither at
4.5 nM nor at 100 nM (Figure 3b). Strikingly, 7.5mM Rottlerin
alone not only increased SN4741 cells viability compared with
untreated cells but also under the experimental conditions
described. Rottlerin also completely blocked the toxic effect
produced by the Ab1–42 peptide while maintaining cell viability
close to 100% (Figure 3b). Finally, we determined the role of
Rac 1 in Ab1–42 peptide-induced toxicity using 6-MP, a
compound described to be a Rac 1 inhibitor.43 Cells were
pretreated for 1 h with 5 mM 6-MP before adding the Ab1–42
peptide and cells viability was analyzed after 24 h. As shown in
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Figure 5 nPKCs and Rac 1 are molecular targets that can block apoptosis of
neurons induced by 1–42 b-amyloid (Ab1–42) peptide. (a) Histogram and
representative fields showing (b) untreated, (c) Ab1–42 peptide (100 nM, 4 days)
toxicity in cultures treated after seven divisions and (d, e) protection when oligomers
are applied in combination with 7.5mM Rottlerin and 25mM NCS23766 (N-(N-(3,5-
difluorophenacetyl-L-alanyl))-S-phenylglycine), respectively; scale bar in (e)
represents 500mm. (a) Bars (gray value per area) represent neuronal apoptosis
occurring in Ab1–42 peptide-treated hippocampus and entorhinal cortex. Bars in (a)
represent the mean±s.e.m. out of five independent experiments for Rottlerin and
three independent experiments for NCS23766. *Po0.05 comparing Ab1–42 peptide
vs Rottlerin or NCS23766 treatment. ECx, entorhinal cortex; CA1, cornu ammonis 1;
CA2-3, cornu ammonis 2-3 of the hippocampus; DG, dentate gyrus; PI, propidium
iodide.
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the toxicity induced by the Ab1–42 peptide. Typically, this
peptide reduced cell culture viability to 50.80%; however,
Rac 1 inhibition of the Ab1–42 peptide-stimulated pathway
increased cell culture viability by 25% from 50.80 to 75.52%.
To examine whether nPKCs mediated Ab1–42 peptide-
stimulated Rac 1 activation, the effect of Rottlerin was tested.
Treatment of SN4741 cells with this inhibitor prevented Rac 1
activation induced by the Ab1–42 peptide (Figure 3c, upper first
panel, lane 4 vs lane2). Ab1–42 peptide also stimulated Rac 1
activation in primary cultures of neurons (Figure 3c, lower first
panel, lane 2). The stimulatory effect of Ab1–42 peptide on
Rac 1 activation in these cell cutures was also abrogated by
treatment with Rottlerin (Figure 3c, lower first panel, lane 4).
Small GTPases activation, including Rac 1, are regulated by
guanine nucleotide exchange factors.2 Some guanine nucleo-
tide exchange factors for Rac 1 have been described to be
activated by tyrosine phosphorylation mediated by tyrosine
kinases, such as Vav proteins,44 by threonine phosphorylation
mediated by PKCs, such as Tiam-1,45 or by serine/threonine
phosphorylation mediated by PKA, such as STEF/Tiam-2.46
Our results indicate that Rac 1 activation was mediated by
PI3K/PDK1/PKCs. This scenery prompted us to test if Tiam-1
could be the link betweenPKCsandRac 1 in theAb1–42 peptide
neurotoxic pathway. To this end, SN4741 cells overexpressing
HA-Tiam-1 were pretreated for 1 h with 7.5mM Rottlerin,
followed by 1.25mM Ab1–42 peptide for 30min. Cells were lysed
and cell lysates were immunoprecipitated as described in the
Materials and methods section. As shown in Figure 3d (line 2),
Ab1–42 peptide induced Tiam-1 threonine phosphorylation,
whereas Rottlerin prevented Tiam-1 threonine phosphorylation
induced by Ab1–42 peptide (Figure 3d, lane 4).
Results presented in Figure 3 suggest that Ab1–42 peptide
stimulates Tiam-1/Rac 1 pathway activation through novel
PKCs. To examine this possibility further, SN4741 cells were
transiently transfected with empty vector as control and with
cDNA encoding the PKCy isoform, which had been rendered
constitutively active.47 Equal Rac 1 expression levels in
SN4741-transfected cells were verified by immunoblotting. As
shown in Figure 3e, overexpression of the constituvely active
isoform of PKCy was enough to induce Rac 1 activation in
SN4741 cells (Figure 3e, lane 3). PKCy overexpression
potentiated Ab1–42 peptide-stimulated Rac 1 activation
(Figure 3e, lane 2 compared with lane 4). However, it was
not possible to detect any effects when cells were transfected
with cDNA encoding for PKCa and PKCe (data not shown).
Equal levels of Rac 1 expression in SN4741-transfected cells
was verified by immunoblotting.
Taken together, these results suggest that the novel PKCs
mediate Tiam-1/Rac 1 activation induced by the Ab1–42
peptide, and point to Rac 1 as a key player in transducing
the toxic message initiated by the Ab1–42 peptide.
Role of Rac 1 in neuronal cell death induced by the
Ab1–42 peptide. Effector molecules for small GTPases
contain a region which binds specifically to the active
conformation of the GTPases.30 With this in mind, it was
hypothesized that overexpression of RBD of PAK1 in primary
cultures of neurons could block death signaling induced by
Ab1–42 peptide, as this RBD would bind to the active
configuration of Rac 1 blocking the signal-transduction
pathway through Rac 1 emanating from exposure to the
Ab1–42 peptide.
As shown in Figure 4, Ab1–42 peptide significantly increased
neuronal apoptosis from basal level (100%) (EGFPþ -
untreated cells) to 340±119% (Figures 4 a, b and e, empty
bars). However, when we examined the effect of Ab1–42
peptide on neurons overexpressing RBD of PAK, we
observed that the construct blocked the toxic effect of
Ab1–42 peptide, as there was no significant difference beween
EGFP-RBDþ -untreated (100±46%) and -treated cells
(136±26%) (Figures 4 c, d and e, solid bars). Prompted by
these findings, the impact of the Rac 1 inhibitor NCS2376648
on the Rac 1-mediated neuronal death induced by Ab1–42
peptide was examined. To this end, primary neurons were
pretreated or not with 25 mM NCS23766 for 1 h followed by
Ab1–42 peptide treatment for 24 h and cell viability was
determined by an MTT assay. As shown in Figure 4f (solid
bars), cell viability correlated inversely with the concentration
of Ab1–42 peptide added. However, NCS23766 efficiently
blocked the toxic effect of the Ab1–42 peptide (Figure 4f,
empty bars).
To strengthen the results obtained with Ab1–42 synthetic
peptide, the ability of soluble brain extracts derived from
18-month-old PS1APP transgenic mice (natural oligomers) to
stimulate Rac 1 activation was also investigated. To this end,
the effects of 10mg of soluble brain extracts from 18-month-
old WT and PS1APP mice on PAK1 phosphorylation were
determined. As shown in Figure 4g, incubation of cell cultures
with 10 mg of soluble brain fractions from PS1APP mice for
30min induced a robust phosphorylation of PAK1 compared
with soluble extract from WT mice. This phosphorylation was
mediated by the activation of Rac 1, as NCS22766 prevented
PAK1 phosphorylation induced by the soluble brain extracts
from PS1APP mice (Figure 4g, compare lines 2 and 3 with
5 and 6).
In addition, we also determined the effect of 18-month-old
mice-derived soluble fractions on neuronal cell death. Primary
neurons were pretreated or not with 25 mM NCS23766 for 1 h
followed by exposition to soluble brain extracts from
18-month-old WT and PS1APP mice for 24 h. Cell viability
was determined by an MTT assay. As expected, soluble
fractions of PS1APP mice reduced to 50% the cell viability
(Figure 4h, solid bars 100±0.1% vs 50±2.5%). However,
NCS23766 blocked the toxic effect induced by these soluble
brain extracts (Figure 4f, solid bar 50±2.5 vs 75±2.4). WT-
derived soluble fractions did not have any measurable effect
on neuronal cell death.
Taken together, these results show that both the synthetic
Ab1–42 peptide, as well as brain-derived soluble fractions from
PS1APP mice induced apoptosis in primary cultures of
neurons and cell death in this context is actively dependent
on Rac 1 activity.
Rottlerin (nPKC inhibitor) and NCS23766 (Rac 1 inhibi-
tor) block Ab1–42 peptide induced neuronal cell death in
organotypic cultures of the hippocampus and the
entorhinal cortex. To determine whether these results
could be reproduced under nearest to the neuronal physio-
logical conditions as possible, we investigated the effects of
nPKCs and Rac 1 inhibition in organotypic cultures of the
Ab1–42 and its putative role on neuronal death
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hippocampus and the entorhinal cortex treated with Ab1–42
peptide. Both cerebral structures are vulnerable in the initial
stages of AD. Organotypic cultures were untreated or treated
with 100 nM Ab1–42 peptide alone or together with 7.5 mM
Rottlerin or 25 mM NCS23766 for 72 h. After which brain
sections were stained with propidium iodide. As shown in
Figure 5a (bars 3 and 4) and c, Ab1–42 peptide induced cell
death in the hippocampus and in the entorhinal cortex.
However, treatment with Rottlerin or NCS23766 efficiently
prevented Ab1–42 peptide-induced cell death in both cerebral
structures: in the hippocampus and in the entorhinal cortex
(Figure 5a (bars 5–8) and d,e). Our results describe for the
first time how Ab1–42 peptide transduces cell death signals
through PI3K/PKD1/nPKC/Rac 1 to induce neuronal cell
death. This characterization also allows us to point out nPKC/
Rac 1 as potential targets to revert the programmed cell
death induced by the Ab1–42 peptide.
Discussion
Functional specificity of small GTPases of the Rho family in
intracellular signaling pathways depends mainly on the
cellular system, type of stimuli and their intracellular localiza-
tion. Regarding the nervous system, GTPases of the Rho
family participate actively controlling cytoskeleton dynamics in
neurons, thereby modulating synaptic plasticity;11 however,
their molecular partners in Ab1–42 peptide-mediated neuronal
toxicity are not known.
Ab1–42 peptide is the primary neurotoxic factor in the
pathogenesis of AD and it can be present in different
molecular structures. To date, the prevailing hypothesis has
been the amyloid cascade,49 where long insoluble polymers
generated by aggregates of the b-amyloid peptide (40–42
amino acids), localized in senile plaques lead to neuronal
death and thus are involved in the development of AD and
other forms of dementia. However, presently there is
additional evidence suggesting that amyloid insoluble fibrils
are not the only toxic forms of the Ab1–42 peptide. It has
been reported that ADDLs cause loss of short-term
synaptic plasticity and selective neuronal death in the long
term and this toxic form of the peptide has become
increasingly more important in the understanding of AD
neuropathogenesis.27,50–52
In this study, we show that ADDLs’ engagement and natural
oligomers from transgenic mice induce a robust Rac 1
activation, triggering a signaling cascade that results in
cellular death. Importantly, we identified PI3K/PDK1/nPKCs
as a specific upstream regulatory pathway for Rac 1 in Ab1–42
peptide-treated cells, and provide new evidence supporting,
on the one hand, the relevance of this cellular death cascade
controlled by ADDLs and on the other hand, the possibility of
using pharmacological inhibition of these signaling molecules
to prevent peptide-induced toxicity in neurons.
The best-characterized neuronal survival pathway
described is the PI3K/AKT cascade53 and it has been
suggested that some neurodegenerative diseases such
as schizophrenia and/or AD this signaling pathway is
altered.54–56 The expression of intracellular Ab1–42 peptide
causes a decrease in the AKT phosphorylation and in the
induction of apoptosis in neurons.57 Recently, it has also been
reported that ADDLs block PDK1-mediated AKT phosphor-
ylation by preventing a direct interaction between them. The
effect of rendering this antiapoptotic pathway non-functional
leads to an increase in neuronal cell death.58 Accordingly, we
observed that when PI3K and AKT basal activities were
blocked with specific inhibitors, cell viability was reduced
and these pretreatments were unable to prevent Ab1–42
peptide-stimulated toxicity in neurons. Nevertheless, pretreat-
ment of SN4741 cells and primary neurons with OSU03012, a
PDK1 inhibitor, prevented not only Rac 1 activation but also
cell death induced by the Ab1–42 peptide. These results
suggest that PDK1 participates in other AKT-independent
signaling pathways.
Indeed, PDK1 can also phosphorylate and activate other
key intracellular signaling molecules, such as PKA,59 p70-
S6K59 and some PKC family members: including the novel
PKCs (d and y).35,36 PKCs are critical components in the
signal-transduction pathways that control not only cell
survival42,60 but also proapoptotic pathways in neurons.61,62
It is still unknown howPKCsmaintain proper balance between
cell survival and apoptosis in neurons. Probably this equili-
brium depends on the different stimuli reaching cells. As
several studies have demonstrated, the novel PKCs are
involved in programmed cell death signaling acting through
proapoptotic signals, and the PKC inhibitor Rottlerin is able to
protect cells from apoptosis induced by H2O2, ultraviolet
radiation, taxol and other toxins.63–67 In addition, it has been
reported that the novel PKCd is activated in response to
oxidative stress stimulated by glutamate61,62 and that PKCd
activation in retinal neurons contributes to apoptosis.68,69 In
agreement with this, we have found that inhibition of novel
PKC (d and y) activities by Rottlerin prevent Rac 1 activation
and apoptosis induced by the Ab1–42 peptide in SN4741 cells,
neuronal primary cultures and organotypic cultures of the
hippocampus and the entorhinal cortex. Therefore, we point
out that nPKCs would be key molecules in cell signaling
mediated by the Ab1–42 peptide and could be actively involved
in neuronal degeneration in AD.
Ab1–42 peptide increases the intracellular concentration of
reactive oxidative species, which cause permanent damage
to brain structures.70,71 Some mechanisms have been
suggested by which Ab1–42 peptide could increase the
concentration of reactive oxidative species. One of them
proposed that Ab would be activating the NADPH oxidase
complex via the canonical pathway involving Rac 1, in both
microglia and other cell types, including monocytes and
neutrophils.72,73 However, another mechanism would involve
PI3K and PKC in the activation of NADPH oxidase by a non-
canonical pathway.74–76 It is also possible that the key to this
process lies in another effector molecule for Rac 1, such as
PAK. In this regard, Ma and co-workers77 have reported that
Rac 1 activation by soluble oligomeric Ab1–42 peptide leads to
aberrant activation and membrane translocation of PAK.
These authors demonstrate an aberrant activation of PAK in
neurons from the hippocampus, inducing an alteration of
dendritic spines that leads to a loss of synaptic contacts
between cells. Related to this, we have found that inhibition of
Rac 1 activity by 6-MP or NCS23766 prevent apoptosis
induced by the Ab1–42 peptide and natural oligomers in
SN4741 cells, neuronal primary cultures and organotypic
Ab1–42 and its putative role on neuronal death
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cultures of the hippocampus and the entorhinal cortex.
Therefore, we postulate that Rac 1 could be another key
molecule downstream of nPKCs in cell signaling mediated by
the Ab1–42 peptide and it could be actively involved in neuronal
degeneration in AD.
In conclusion, we have characterized the signaling pathway
PI3K/PDK1/nPKCs/Rac 1 involved in cellular toxicity induced
by the Ab1–42 peptide. Furthermore, this signaling pathway
has allowed us to identify PDK1, nPKC and Rac 1, as putative
therapeutic targets given that their inhibition is able to protect
neurons from cell death induced by the Ab1–42 peptide or
natural oligomers, albeit nPKCs inhibition do so more
efficiently. However, the receptor system through which
Ab1–42 peptide delivers death signals through PI3K/PDK1/
nPKC/Rac 1 pathway is still unknown. There is mounting
evidence indicating a direct interaction between the Ab1–42
peptide with the post-synaptic receptors, such as N-methyl-D-
aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA0 and/or a-7-nicotine acetylcholine
receptors.78 Future studies will allow us to characterize the
receptors and signaling molecules that participate upstream
of this signal-transduction pathway.
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